Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.73 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14634420 | 1.00 | GPR119 (0.73) | GPR119EPHX2HRH3HRH1MAPT | |
| SCHEMBL3285206 | 0.95 | GPR119 (0.65) | GPR119EPHX2HRH3HRH1MAPT | |
| SCHEMBL2556516 | 0.86 | GPR119 (0.69) | GPR119EPHX2HRH3HRH1MAPT | |
| SCHEMBL2556517 | 0.86 | GPR119 (0.69) | GPR119EPHX2HRH3HRH1MAPT | |
| SCHEMBL2548521 | 0.84 | GPR119 (0.69) | GPR119EPHX2HRH3HRH1MAPT | |
| SCHEMBL2555904 | 0.84 | GPR119 (1.00) | GPR119 | |
| SCHEMBL2555906 | 0.84 | GPR119 (1.00) | GPR119 | |
| SCHEMBL12283315 | 0.84 | GPR119 (0.72) | GPR119EPHX2HRH3HRH1NPY2R | |
| SCHEMBL2556384 | 0.84 | GPR119 (0.72) | GPR119EPHX2HRH3HRH1NPY2R | |
| SCHEMBL2548523 | 0.84 | GPR119 (0.69) | GPR119EPHX2HRH3HRH1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556056-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| WO-2011127051-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, SLC5A2, SLC5A1 | GPR119 1/4885EPHX2 2795/4885HRH3 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.